As the transition to digital healthcare accelerates Artificial intelligence medical devices The market is growing explosively. Now, beyond simple technology development Data quality과 security systemPerfect preparation for licensing, complete with everything up to [the limit], is the key to market entry. Today, regarding what many people are curious about Key Points on the Institutionalization of AI Medical Devices과 complex licensing proceduresI will organize it efficiently for you.
The purpose of the institutionalization of AI medical devices is to drastically shorten the time to enter the medical field by integrating licensing procedures and flexibly improving clinical and GMP reviews, while reflecting their software-centric characteristics.
Changes in the AI medical device system
In the past, AI software and the devices running it were often reviewed separately, resulting in significant time and cost consumption. However, the recent regulatory environment is single licensing systemIt is transitioning and moving toward recognizing devices equipped with AI software as medical devices. Streamlining of proceduresIt plays a decisive role in reducing the burden on manufacturers and accelerating the commercialization of products.
The government is promoting the creation of an ecosystem by providing dedicated data vouchers for medical AI and refining regulatory guidelines. In particular, it is focusing on enhancing the safety of software directly utilized in the medical field, such as for diagnosis and treatment prediction, moving beyond the simple supply of equipment. Digital Medical Products ActDetailed guidelines based on [the above] present customized regulatory proposals that take into account the technical specificity of AI products.
What are the key requirements for AI medical devices?
Even if technical capabilities are outstanding, approval cannot be obtained if the standards required by regulatory agencies are not met. Data Bias ManagementOne of the most challenging parts is ensuring the representativeness of the training data and Continuous monitoringYou must perform this. In addition, it is essential to verify performance indicators such as the accuracy and sensitivity of the algorithm with objective data.
Cybersecurity measures have also been strengthened in proportion to the handling of patient information. We analyzed the vulnerabilities of the AI model and Data leakage preventionAccess control technology must be designed for this. In particular, since devices equipped with generative AI must additionally prove the reliability and explainability of their outputs, from the early development stage Design reflecting regulatory requirementsis required.
Streamlining of licensing procedures and expected effects
Once designated as an AI and digital innovation medical device, the review and evaluation processes are integrated, significantly reducing the time required for market entry. Companies have high expectations, as the procedure, which previously took about 390 days, can be shortened to around 80 days. GMP On-site Inspection As expected, switching to document review after the initial screening, etc. Significantly relieves the burden of on-site inspectionsI am doing it.
The following is a table comparing the key items of the changes to the AI medical device system.
| division | Before change | After change |
|---|---|---|
| licensing method | Individual review | Single permit |
| Review period | Relative long term | Shortening when designating innovative devices |
| GMP investigation | Repeated field investigations | Switch to document review |
Significance of Expanding the Scope of Acceptance for Clinical Trial Data
Clinical trials are the stage in the medical device development process that requires the most cost and time. Regulatory authorities require not only prospective clinical trial data Retrospective clinical dataWe are reducing the burden of preparation for companies by expanding the scope of recognition to include [specific area]. This is Clinical efficacyWe help innovative AI technologies quickly take root in the field by diversifying methods for proving their validity.
This flexible system operation moves beyond the era where simply creating good technology was enough, and now involves the convergence of data quality and safety management. Designed within standardsThis suggests that it is important to do so. Companies must prepare the entire process, from drafting clinical trial protocols to statistical analysis, in accordance with a professional documentation system to ensure stable approval.
Checkpoints for Successful Market Entry
Amid the steady increase in the number of AI medical device approvals, along with technical completeness Regulatory Response StrategyIt is a necessity, not an option. It is advantageous to systematically prepare from the beginning by receiving assistance from a professional partner for aspects that are difficult to handle alone, such as drafting technical documents or establishing a quality management system.
Utilizing an integrated solution that covers everything from product design to security enhancement and post-management is a great help in overcoming unexpected regulatory barriers. Changing regulatory environmentI hope you take this opportunity to successfully enter the market and achieve a sustainable technological leap.
Frequently Asked Questions
How have the licensing procedures for AI medical devices changed?
The review period has been significantly shortened by transitioning from the existing complex individual review method to a single licensing system that integrates software and devices.
What are the data requirements for developing AI medical devices?
Bias must be managed by ensuring the representativeness of the training data, and objective performance indicators such as the accuracy and sensitivity of the algorithm must be proven.
How has the burden of GMP on-site inspections on AI medical device manufacturers been reduced?
After the initial review, we introduced a method of switching from on-site inspections to document reviews, which significantly reduced the administrative burden on manufacturers.
Has the scope of accepted clinical trial data submissions been expanded?
We have further diversified the methods for proving clinical efficacy by expanding the scope of acceptance to include not only prospective clinical trial data but also retrospective clinical data.